Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs

This article was originally published in The Tan Sheet

Executive Summary

Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.

You may also be interested in...

President Urges End To Corporate Inversions

In his State of the Union speech, President Obama pledges to “close tax loopholes,” including his continuing efforts to ban U.S. firms from moving their tax headquarters overseas in corporate inversion deals. On the same day Democratic legislators introduced a bill to stop corporate inversions.

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts